Target of Interest
Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
产品信息
Z2103MP
产品规格
种属反应
Human
宿主/亚型
Mouse
/ IgG1, kappa
分类
Monoclonal
类型
Antibody
克隆号
1G12
抗原
A fragment containing the last 70 amino acids of the core glypican-3 protein
偶联物
Unconjugated
形式
Liquid
纯化类型
Protein A
保存液
tris with BSA, NP-40
内含物
<0.1% sodium azide
保存条件
4° C
运输条件
Ambient (domestic); Wet ice (international)
产品详细信息
This product is diluted and in a ready-to-use formulation.
A recommended positive control tissue for this product is HCC, however positive controls are not limited to this tissue type.
The primary antibody is intended for laboratory professional use in the detection of the corresponding protein in formalin-fixed, paraffin-embedded tissue stained in manual qualitative immunohistochemistry (IHC) testing. This antibody is intended to be used after the primary diagnosis of tumor has been made by conventional histopathology using non-immunological histochemical stains.
Glypican-3 (GPC3) is a member of the glypican family of glycosyl phosphatidylinositol-anchored cell-surface heparan sulfate proteoglycans. The 1G12 monoclonal antibody has been used to assess GPC3 expression in malignant and nonmalignant liver tissue samples by immunohistochemistry in formalin-faxed and paraffin-embedded tissue. Studies have shown that GPC3 is expressed at the protein level in most hepatocellular carcinomas, but it is undetectable in normal liver and benign hepatic lesions, including dysplastic and cirrhotic nodules. In addition, GPC3 is significantly elevated in the serum of a large proportion of patients with hepatocellular carcinoma. Based on these results, it has been proposed that GPC3 could be a useful marker to differentiate between benign and malignant liver diseases.
Antibody is used with formalin-fixed and paraffin-embedded sections. Pretreatment of deparaffinized tissue with heat-induced epitope retrieval or enzymatic retrieval is recommended. In general, immunohistochemical (IHC) staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody (link antibody), an enzyme complex and a chromogenic substrate with interposed washing steps. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.
A positive tissue control must be run with every staining procedure performed. This tissue may contain both positive and negative staining cells or tissue components and serve as both the positive and negative control tissue. External Positive control materials should be fresh autopsy/biopsy/surgical specimens fixed, processed and embedded as soon as possible in the same manner as the patient sample (s). Positive tissue controls are indicative of correctly prepared tissues and proper staining methods. The tissues used for the external positive control materials should be selected from the patient specimens with well-characterized low levels of the positive target activity that gives weak positive staining. The low level of positivity for external positive controls is designed to ensure detection of subtle changes in the primary antibody sensitivity from instability or problems with the staining methodology. A tissue with weak positive staining is more suitable for optimal quality control and for detecting minor levels of reagent degradation.
Internal or external negative control tissue may be used depending on the guidelines and policies that govern the organization to which the end user belongs to. The variety of cell types present in many tissue sections offers internal negative control sites, but this should be verified by the user. The components that do not stain should demonstrate the absence of specific staining, and provide an indication of non-specific background staining. If specific staining occurs in the negative tissue control sites, results with the patient specimens must be considered invalid.
靶标信息
GPC3 is a cell surface proteoglycan that bears heparan sulfate. This protein may be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs, and may play a role in the modulation of IGF2 interactions with its receptor and thereby modulate its function. Members of the glypican-related integral membrane proteoglycan family contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol (GPI) linkage. These proteins may play a role in the control of cell division, growth regulation, and tumor predisposition. Deletion mutations in GPC3 are the cause of Simpson-Golabi-Behmel syndrome (SGBS), also known as Simpson dysmorphia syndrome (SDYS). SGBS is a condition characterized by pre- and postnatal overgrowth (gigantism) with visceral and skeletal anomalies.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
生物信息学
蛋白别名: glypican proteoglycan 3; Glypican-3; GTR2-2; GTR22; heparan sulphate proteoglycan; Intestinal protein OCI-5; MXR7; secreted glypican-3
基因别名: DGSX; GPC3; GTR2-2; MXR7; OCI-5; OCI5; SDYS; SGB; SGBS; SGBS1
UniProt ID: (Human) P51654
Entrez Gene ID: (Human) 2719
retinoid metabolic process
branching involved in ureteric bud morphogenesis
glycosaminoglycan biosynthetic process
glycosaminoglycan catabolic process
anatomical structure morphogenesis
anterior/posterior axis specification
body morphogenesis
negative regulation of peptidase activity
glycosaminoglycan metabolic process
bone mineralization
osteoclast differentiation
lung development
positive regulation of BMP signaling pathway
embryonic hindlimb morphogenesis
positive regulation of protein catabolic process
positive regulation of endocytosis
negative regulation of smoothened signaling pathway
positive regulation of smoothened signaling pathway
negative regulation of growth
positive regulation of glucose import
negative regulation of epithelial cell proliferation
coronary vasculature development
mesenchymal cell proliferation involved in ureteric bud development
mesonephric duct morphogenesis
cell proliferation involved in metanephros development
negative regulation of canonical Wnt signaling pathway
positive regulation of Wnt signaling pathway, planar cell polarity pathway
